<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="(ABCC1 or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and" exact="breast cancer" post="resistance protein (ABCG2 or BCRP). Inhibitors of AETs may"/>
 <result pre="or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and breast" exact="cancer" post="resistance protein (ABCG2 or BCRP). Inhibitors of AETs may"/>
 <result pre="Herpes Simplex Virus type 1 (HSV-1) can cause potentially fatal" exact="encephalitis" post="in developed countries [5,6]. Finally, mice intra-nasally infected by"/>
 <result pre="Encephalitis Virus (VEEV) show a CNS phase that results in" exact="encephalitis" post="and death [7,8,9]. Human Immunodeficiency Virus type-1 (HIV-1) belongs"/>
 <result pre="The presence of HIV in the brain can lead to" exact="dementia" post="in the more severe cases [13,14]. The CNS therefore"/>
 <result pre="can cause severe side effects, such as lipodystrophy, diabetes, and" exact="cardiovascular disease" post="[21]. 2. Active Efflux Transporters Do Not Allow the"/>
 <result pre="aspects into account, it has been suggested that the targeted" exact="suppression" post="of P-gp expression in the HIV-1-infected reservoirs of the"/>
 <result pre="against neurotropic viral effects was tested on mice infected by" exact="herpes simplex" post="virus type 1 (HSV-1). In particular, mice models of"/>
 <result pre="virus type 1 (HSV-1). In particular, mice models of HSV-1" exact="encephalitis" post="received an intranasal pretreatment with the immunostimulant polyinosinic:polycytidylic acid"/>
 <result pre="canine distemper virus (CDV) and also indicated for treatment of" exact="hepatitis" post="C [84], allowed investigators to obtain drug concentrations in"/>
 <result pre="induces a reduction in viral replication as evidenced by the" exact="suppression" post="of supernatant HIV-1 p24 levels and by the reduction"/>
 <result pre="United States and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular" exact="stomatitis" post="virus infection of immunodeficient miceJ. Virol.199367669867068105106 3.Van den PolA.N.DaltonK.P.RoseJ.K.Relative"/>
 <result pre="fluorescent envelope glycoproteinJ. Virol.2002761309132710.1128/JVI.76.3.1309-1327.200211773406 4.Van den PolA.N.DavisJ.N.Highly attenuated recombinant vesicular" exact="stomatitis" post="virus VSV-12’GFP displays immunogenic and oncolytic activityJ. Virol.2013871019103410.1128/JVI.01106-1223135719 5.TylerK.L.Update"/>
 <result pre="virus VSV-12’GFP displays immunogenic and oncolytic activityJ. Virol.2013871019103410.1128/JVI.01106-1223135719 5.TylerK.L.Update on" exact="herpes simplex" post="encephalitisRev. Neurol. Dis.2004116917816400278 6.WhitleyR.J.KimberlinD.W.Herpes simplex encephalitis: Children and adolescentsSemin."/>
 <result pre="vivo define early steps in the pathogenesis of Venezuelan equine" exact="encephalitis" post="virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine encephalitis"/>
 <result pre="equine encephalitis virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine" exact="encephalitis" post="virus-induced disease in the mouseVirology200128419020210.1006/viro.2001.087811384219 9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach"/>
 <result pre="9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach to the study of Venezuelan equine" exact="encephalitis" post="virus pathogenesisArch. Virol. Suppl.19949991098032286 10.PomerantzR.J.Reservoirs, sanctuaries and residual disease:"/>
 <result pre="into the central nervous system?Curr. Pharm. Des.2011173560357610.2174/13816121179819448622074427 28.PavanB.PaganettoG.RossiD.DalpiazA.Multidrug resistance in" exact="cancer" post="or inefficacy of neuroactive agents: Innovative strategies to inhibit"/>
 <result pre="protease inhibitors are inhibitors but not substrates of the human" exact="breast cancer" post="resistance protein (BCRP/ABCG2)J. Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein"/>
 <result pre="inhibitors are inhibitors but not substrates of the human breast" exact="cancer" post="resistance protein (BCRP/ABCG2)J. Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein"/>
 <result pre="drugs in human brain microvessel endothelial cellsAntimicrob. Agents Chemother.2013574481448810.1128/AAC.00486-1323836171 65.ShuklaS.OhnumaS.AmbudkarS.V.Improving" exact="cancer" post="chemotherapy with modulators of ABC drug transportersCurr. Drug Targets20111262163010.2174/13894501179537854021039338"/>
 <result pre="pretreatment with toll-like receptor agonists in a mouse model of" exact="herpes simplex" post="virus type 1 encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro efficacy"/>
 <result pre="potent humoural immunityArtif. Cells Nanomed. Biotechnol.2018151910.1080/21691401.2018.143845029447484 92.HuliszD.Efficacy of zinc against" exact="common cold" post="viruses: An overviewJ. Am. Pharm. Assoc.20044459460310.1331/1544-3191.44.5.594.Hulisz 93.SeremetaK.P.ChiappettaD.A.SosnikA.Poly(ε-caprolactone), Eudragit® RS"/>
 <result pre="Res.1992933233810.1023/A:10158347011361614966 112.CunninghamA.L.NaifH.SaksenaN.LynchG.ChangJ.LiS.JozwiakR.AlaliM.WangB.FearW.et al.HIV infection of macrophages and pathogenesis of AIDS" exact="dementia" post="complex: Interaction of the host cell and viral genotypeJ."/>
</results>
